Dimethaid appoints new CEO
TORONTO, Sept. 22 /CNW/ - Pharmaceutical developer Dimethaid Research Inc. (TSX: DMX) has announced the appointment of Dr. Henrich R.K. Guntermann as president and chief executive officer. Dr. Guntermann was elected director at the company's annual general meeting, held September 21, 2004. Dr. Guntermann is a medical doctor with over ten years experience in the health care sector including business development, restructuring and corporate finance. He has also worked as a clinician and researcher at the University Hospital in Zurich, Switzerland. In 1998, Dr. Guntermann co-founded BioAlliance AG, a German life sciences private equity and consulting firm. Dr. Guntermann received his medical doctorate at the Philipps-University in Marburg, Germany. He has also received a masters of science in biology, with specialization in pharmacology/toxicology and human genetics. Dr. Guntermann is in the process of relocating to Canada. In addition, Daniel H. Chicoine has been appointed chairman of the board and John C. London has been appointed corporate secretary. The company has also formed a Corporate Governance and Compensation Committee, consisting of Dr. Klaus von Lindeiner, John C. London and Dr. Jacques Messier. Members of the Audit and Environmental Committee include Dr. Klaus von Lindeiner, David A. Copeland and Anthony E. Dobranowski. |